Research news

Research news

23 November 2018

The Testosterone Trials show that testosterone therapy confers significant and clinically meaningful health benefits in older men with low testosterone levels. Even though the Testosterone Trials aimed to recruit men with hypogonadism due to no apparent reason other than age, in fact the majority of enrolled men were obese and more than one third had type 2 diabetes. Obesity, metabolic syndrome and/or type 2 diabetes are stronger risk factors for hypogonadism than aging per se. Consequently, the Testosterone Trials provide compelling evidence that testosterone therapy confers significant benefits in the growing population of men with obesity and/or type 2 diabetes.

Read article
15 October 2018

A new study was recently published in The Aging Male which treated hypogonadal patients with type 2 diabetes who had recently suffered a stroke with testosterone undecanoate. During the acute phase of stroke, patients received standard treatment with reperfusion, anti-hypertensives and anti-coagulants etc. but testosterone was started as soon as 1 week later.

After 5 years of testosterone undecanoate treatment, there was a marked reduction of incident stroke and mortality. More patients receiving testosterone were able to return to work, compared to the untreated control group. The increased survival seen after 5 years of testosterone undecanoate treatment is accompanied by:

Read article
15 September 2018

A long-held belief is that high testosterone levels increase risk of prostate cancer. To the contrary, most studies show that it is low testosterone that increases risk of prostate cancer. Furthermore, emerging data – summarized here - suggest that it may not be the absolute level of testosterone that predicts prostate cancer development, but rather patterns of change in testosterone levels, such as steep declines with age or reductions in testosterone at younger age. Maintaining stable testosterone levels throughout lifespan with testosterone therapy may have a significant impact on prostate cancer prevention.

Read article
15 August 2018

Hypogonadism (testosterone deficiency) is more common than previously thought, even in younger men. Men with hypogonadism – regardless of age – have a higher prevalence of muscle weakness and simultaneous occurrence of several risk factors and chronic diseases.

Considering the strong association between low testosterone and multimorbidity even in young men, it is possible that low testosterone may play a causal role in chronic disease development, such as obesity, metabolic syndrome, cardiovascular disease and type 2 diabetes, the prevalence of which has reached epidemic proportions over the last decade. Early detection and treatment of low testosterone, particularly in younger men, could possibly slow progression, or potentially stop disease development entirely.

 

Read article
15 July 2018

Low bone mineral density is a prevalent and treatable cause of osteoporosis and its associated morbidity and mortality in men with hypogonadism. The Bone Trial of the Testosterone Trials - a series of the largest studies to date on the effects of testosterone therapy in hypogonadal men - unequivocally showed that testosterone therapy significantly increases bone mineral density and estimated bone strength. This would be expected to reduce osteoporosis and fractures.

Read article
15 June 2018

Occasionally a concern about testosterone therapy is heart disease risk. New medical research data is rapidly accumulating, showing that testosterone therapy – in contrast to what is sometimes believed – reduces risk factors for heart disease and improves vascular function. Here we present a study showing that testosterone therapy improves insulin sensitivity, glycemic control and endothelial function, while reducing atherosclerotic severity.

Read article
15 May 2018

Clinical practice guidelines on hypogonadism and testosterone therapy aim to help clinicians diagnose and treat men who present with hypogonadism. However, due to lack of scientific data on several issues, guidelines recommendations inevitably contain an element of opinion, which is why there are contradictions between some recommendations issued by different guidelines. 

Read article
15 April 2018

The most widely known effect of testosterone therapy is improved sexual function. But testosterone therapy actually has a wide range of physiological effects in men, including increased muscle mass, decreased fat mass (both overall and belly fat), improved insulin sensitivity, reduced risk of the metabolic syndrome and type 2 diabetes, improved mood / depressive symptoms, energy, and quality of life, reduced lower urinary tract symptoms, and importantly, reduced risk of all-cause and cardiovascular mortality.

Read article
15 March 2018

STUDY: Dimitriadis GK, Randeva HS, Aftab S, et al. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018. Feb 2. [Epub ahead of print]

Read article
15 February 2018

STUDY: Haider A, Haider KS, Saad F. Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. Endocrinology, diabetes & metabolism case reports. 2017; Sept 14.

The number of patients with type 2 diabetes is increasing rapidly in both developed and developing countries around the world. The emerging pandemic is driven by the combined effects of population ageing, rising levels of obesity, sedentary lifestyle and unhealthy food habits. The prevalence of type 2 diabetes is around 12% in Western countries, and rises to 25% among those aged >65 years.

Read article
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Wed, 05/02/2020

Bayer logo